Teleflex to Present Innovative New Vascular Access Technologies at World Congress on Vascular Access 2016 ("WoCoVA"), in Lisbon, Portugal

WAYNE, Pa.--()--Teleflex Incorporated (NYSE: TFX) will showcase three Arrow® Products at the World Congress of Vascular Access (WoCoVA) in Lisbon June 22-24 in preparation for their international launch.

During the Congress, Teleflex’s primary focus will be on our PICC (Peripherally Inserted Central Catheters) and JACC (Jugular Axillo-Central Catheter) product families featuring antithrombogenic and antimicrobial Chlorag+ard® Technology. In addition to the global expansion of Chlorag+ard® Technology, we will be showcasing the all new Arrow® VPS Rhythm™ System (currently under review for CE mark).

Chlorag+ard® Technology is the 3rd generation of chlorhexidine-based protective treatment from the Arrow brand. As shown in in vivo and in vitro studies, Chlorag+ard® Technology provides antithrombogenic (92% reduction in thrombus accumulation on catheter surfaces on an in vivo ovine model when challenged with Staphylococcus aureus)1 and antimicrobial properties (99.99% colonization reduction in gram +, gram – bacteria and fungal pathogens in an in vitro study)2, reduced thrombotic occlusion3 and a reduction in phlebitis and intimal hyperplasia (an average of 72% less intimal hyperplasia)4. Arrow® Catheters with Chlorag+ard® Technology provide protection for at least 30 days.

The Arrow® VPS Rhythm™ System provides ECG-based tip confirmation in a highly portable, lightweight and versatile design (the system can be used in combination with every type of central venous access). The Arrow® VPS Rhythm™ System with ECG Technology assists in placement and confirmation of the catheter tip in the SVC-CAJ (superior vena cava-cavoatrial junction), and may be used with a broad range of catheter types. When paired with the VPS® TipTracker™ Stylet, the Arrow® VPS Rhythm™ System with TipTracker™ Technology provides real-time catheter navigation and ECG-based tip positioning, with a visual blue line that tracks along the catheter pathway.

These innovative products will join our market-leading Arrow® CVC with Arrowg+ard® Antimicrobial Technology and the Arrow® EZ-IO® Intraosseous Access System enabling clinicians to expand their options when choosing the Right Line for the Right Patient at the Right Time.

During WoCoVA on Thursday, June 23, a symposium titled “The Missing Link in Vascular Access” will take place discussing new technologies that may represent the missing link in complication reduction and vascular access device (VAD) selection. The symposium will be hosted by Jim Lacy, BSN, RN, VA-BC and features presentations by Mauro Pittiruti, MD and Massimo Lamperti, MD.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rüsch® and Weck® – trusted brands united by a common sense of purpose.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, the Teleflex logo, Arrow, Arrowg+ard, Chlorag+ard, Deknatel, EZ-IO, Hudson RCI, LMA, Pilling, Rüsch, TipTracker, VPS and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. © 2016 Teleflex Incorporated. All rights reserved.

VA-BC is a trademark of the Vascular Access Certification Corporation.

References:
1. As compared to uncoated PICCs, intravascular ovine model inoculated with Staph aureus. No correlation between in vitro / in vivo testing methods and clinical outcomes have currently been ascertained.
2. In vitro data on file 2010. No correlation between in vitro / in vivo testing methods and clinical outcomes have currently been ascertained.
3. As compared to uncoated PICCs, in vitro model measuring flush pressure post exposure to human blood. No correlation between in vitro / in vivo testing methods and clinical outcomes have currently been ascertained.
4. As compared to uncoated PICCs, intravascular ovine model. No correlation between in vitro / in vivo testing methods and clinical outcomes have currently been ascertained.

Contacts

Teleflex Incorporated
Jake Elguicze
Treasurer and Vice President, Investor Relations
610-948-2836
or
Martina Teichmann-Zindler
Director Marketing Communications International
+49 (0)7151-406-538
martina.teichmann@teleflex.com

Release Summary

Teleflex to Present Innovative New Vascular Access Technologies at World Congress on Vascular Access 2016 (“WoCoVA”), in Lisbon, Portugal

Contacts

Teleflex Incorporated
Jake Elguicze
Treasurer and Vice President, Investor Relations
610-948-2836
or
Martina Teichmann-Zindler
Director Marketing Communications International
+49 (0)7151-406-538
martina.teichmann@teleflex.com